US FDA places clinical hold on Iovance's lung cancer treatment trial (updated)

Iovance Biotherapeutics

27/12/2023 12:21

(Rewrites first paragraph, adds further details in paragraphs 3
to 5)
       Dec 27 (Reuters) - The U.S. Food and Drug Administration
has placed a clinical hold on Iovance Biotherapeutics'  IOVA.O 
lung cancer therapy trial after a patient death, the company
said on Wednesday.
    Shares of the company were down 26.9% in premarket trading.
    The company said that it will pause enrollment in trial
studying LN-145 TIL during the hold, while patients who were
previously treated with the therapy for non-small cell lung
cancer will continue to be monitored.
    The company said that it will work with the FDA to safely
resume enrollment as soon as possible. 
    Non-small cell lung cancer is a disease in which cancer
cells form in the tissues of the lung.

 (Reporting by Christy Santhosh; Editing by Shailesh Kuber)
 ((Christy.Santhosh@thomsonreuters.com;))